Inactive Instrument

Press Releases Neoprobe Corporation Nyse

Equities

NEOP

US6405181065

End-of-day quote Nyse Other stock markets
- ^USD	-

06-21	Navidea Biopharmaceuticals, Inc. Announces Board Resignations	CI
2023	Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	12-04	AQ
Navidea: Q3 Earnings Snapshot	11-15	AQ
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	23-10-05	BU
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	23-08-10	BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	23-07-31	AQ
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities	23-07-31	BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	23-07-28	BU
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	23-07-27	BU
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down	23-07-13	BU
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	23-07-03	AQ
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	23-06-30	BU
NAVIDEA BIOPHARMACEUTICALS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-06-16	AQ
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock	23-06-16	BU
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment	23-06-16	BU
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update	23-06-07	BU
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	23-06-05	AQ
NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	23-06-05	AQ
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	23-06-02	BU
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down	23-06-01	BU
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market	23-05-22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neoprobe Corporation Nyse

Equities

NEOP

US6405181065

Press Releases

Filters